We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.
Your email address will not be published. Required fields are marked *
Comment
Name *
Email *
Website
Notify me of new posts by email.
Leave a Reply